View Full Version : VEGFR-TKI Related Hemorrhages Usually Mild in Cancer Patients

Thu 24th October '13, 11:48pm
By David Douglas

NEW YORK (Reuters Health) Aug 28 - In cancer patients, use of vascular endothelial growth factor receptor-tyrosine-kinase inhibitors (VEGFR-TKIs) is linked to more hemorrhagic events, but these generally aren't high grade, according to Chinese researchers.

"Based on our findings, we could conclude that while the use of VEGFR-TKIs is associated with a significantly increased risk of developing hemorrhagic events in cancer patients, this is primarily for lower grade events," Dr. Yang Yao told Reuters Health by email.

"The use of VEGFR-TKIs is safe," continued Dr. Yao, "and could be continued in those patients with minor recent hemorrhage."

In an August 6th online paper in the Annals of Oncology, Dr. Yao of Shanghai Jiao Tong University and colleagues report on a meta-analysis of 27 randomized trials involving more than 5000 patients.

"Although angiogenesis inhibitors present a favorable toxicity profile in comparison with traditional chemotherapy agents, hemorrhagic events are emerging as one of the most common adverse events of these agents," they note.

The overall incidence was 9.1% for all-grade hemorrhagic events and 1.3% for high-grade events. VEGFR-TKIs were associated with a significantly increased risk of hemorrhagic events, with a relative risk of 1.67 - but not an increased risk for high-grade hemorrhagic events.

The risk of developing all-grade hemorrhagic events varied significantly with tumor types. Risks were highest for gastrointestinal stromal cancer and were lowest in patients with small-cell lung cancer. There were also significant variations depending on the VEGFR-TKIs employed.

The most common all-grade hemorrhagic events were hemoptysis (48.6%) and epistaxis (20.7%). Among high-grade events, the most common were also hemoptysis (41.8%) followed by CNS hemorrhage (13.4%).

In all, the researchers conclude, the treatment is safe. However, Dr. Yao added, "a close monitoring for hemorrhagic events is recommended."

SOURCE: Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials (http://bit.ly/16Rm4QD)

Thu 24th October '13, 11:51pm

I think in this brief report, Dr. Yao did not define the type of this adverse effect. Is it type A or type B adverse effect? Is it dose related?

Sat 26th October '13, 11:18pm
Hi, Cheney

I have gotten the original source, the original PDF.